Grant: Engage Grants Program
McMaster University
$25,000.00
High quality screening of pharmacological chaperones for protein misfolding disorders
FY 2013-14
Summary
A variety of human diseases are related to protein misfolding (e.g., Alzheimer's disease), including genetic disorders that result in severe enzyme deficiency or aberrant protein function with devastating impacts on human health. For instance, phenylketonuria (or PKU) is one of the most common metabolic disorders that contribute to premature death and impaired mental development in affected children if left untreated. Thus, early detection and treatment intervention is critical for enhancing quality of life and reducing public healthcare expenditures that is central to newborn screening initiatives across Canada.We propose to develop a novel drug screening tool relevant to the discovery of small molecules that assist in refolding mutant or misfolded protein using capillary electrophoresis with whole-column imaging detection (CE-WCID) in partnership with a local instrument manufacturer, Advanced Electrophoresis Solutions (AES). CE-WCID offers a promising yet unrecognized platform for continuous monitoring of fast kinetic processes in free solution, such as protein refolding. Pharmacological chaperones (PCs) represent a novel class of therapeutic agent that bind, stabilize and restore function to misfolded protein. Unlike recombinant protein, PCs can be administered orally with lower production costs while allowing for treatment of life-threatening genetic diseases that do not respond well to conventional therapy, such as Gaucher disease. Overall, our work will showcase the unique merits of CE-WCID for high-quality drug screening of PCs that is urgently neededfor improved patient care based on enzyme enhancement therapy. This project will also provide AES an innovative application to expand commercial interests in marketing their technology to the bio-pharmaceutical industry for the development of orphan drugs that target rare diseases in the population.
Program
Engage Grants Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
462132-2013
Name nom
BritzMcKibbin, Philip
Department département
Chemistry & Chemical Biology
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2013
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3503
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Separation methods
Research subject fr
Méthodes de séparation
Partie
1
Nb partie
1
Application title
High quality screening of pharmacological chaperones for protein misfolding disorders
Keyword
NSERC
Application summary
A variety of human diseases are related to protein misfolding (e.g., Alzheimer's disease), including genetic disorders that result in severe enzyme deficiency or aberrant protein function with devastating impacts on human health. For instance, phenylketonuria (or PKU) is one of the most common metabolic disorders that contribute to premature death and impaired mental development in affected children if left untreated. Thus, early detection and treatment intervention is critical for enhancing quality of life and reducing public healthcare expenditures that is central to newborn screening initiatives across Canada.We propose to develop a novel drug screening tool relevant to the discovery of small molecules that assist in refolding mutant or misfolded protein using capillary electrophoresis with whole-column imaging detection (CE-WCID) in partnership with a local instrument manufacturer, Advanced Electrophoresis Solutions (AES). CE-WCID offers a promising yet unrecognized platform for continuous monitoring of fast kinetic processes in free solution, such as protein refolding. Pharmacological chaperones (PCs) represent a novel class of therapeutic agent that bind, stabilize and restore function to misfolded protein. Unlike recombinant protein, PCs can be administered orally with lower production costs while allowing for treatment of life-threatening genetic diseases that do not respond well to conventional therapy, such as Gaucher disease. Overall, our work will showcase the unique merits of CE-WCID for high-quality drug screening of PCs that is urgently neededfor improved patient care based on enzyme enhancement therapy. This project will also provide AES an innovative application to expand commercial interests in marketing their technology to the bio-pharmaceutical industry for the development of orphan drugs that target rare diseases in the population.